Wir sind mit live! Mehr erfahren

Cencora

COR

Börsenwert 65,1 Mrd. $

340,92 USD

-0,49

0,14 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

340,92

0,00

0 %

1 Tag

-0,14 %

5 Tage

4,78 %

1 Monat

7,04 %

3 Monate

10,69 %

6 Monate

5,75 %

Seit Jahresbeginn

0,6 %

1 Jahr

6,74 %

5 Jahre

187,99 %

10 Jahre

327,54 %

Profil: Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Mitarbeiter: 51.000

Gesundheitswesen Medizinischer Großhandel

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 63,4 %

Neutral 31,7 %

Negativ 4,9 %

AI Disruption May Benefit Cencora More Than Hims & Hers

Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements have driven adjusted operating income up 17% YoY, outpacing 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x—about 25% below sector median—COR merits a 12.5% re-rating, targeting $365–$366 per share.

AI Disruption May Benefit Cencora More Than Hims & Hers

Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific business and macro fundamentals remain supportive. An investment-grade rating, positive operating cash flow, dividend safety, and an improved operating margin underscore the thesis.

Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.Participating in the conference call will be:Robert P. Mauch, President & Chief Executive OfficerEva C. Boratto, Executive Vice President & Chie.

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executive Chair of Ryder System, Inc., where he previously served as Chair and Chief Executive Officer until his retirement in March 2026. Prior to being appointed CEO in 2013, Mr. Sanchez spent two decades with Ryder serving in roles of increasing responsibility including President an.

Cencora Elects Robert E. Sanchez to Its Board of Directors

Zacks Investment Research

Here's Why Cencora (COR) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Cencora (COR) is a Strong Growth Stock

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027

Cencora NYSE: COR executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses.

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora NYSE: COR executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Zacks Investment Research

Here's Why Cencora (COR) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Cencora (COR) is a Strong Value Stock

Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt